Skip to main content
. 2023 Jan 11;18(1):19. doi: 10.1007/s11657-023-01210-4

Fig. 2.

Fig. 2

Patient demographics association with persistence after 2 years by treatment cohort among patients without malignancy at baseline initiating treatment in 2010–2016. Please note different scale on x-axis for Risedronate compared to the other three treatments